Rosiglitazone and cardiovascular risk [4]

New England Journal of Medicine

Volumn 357, Issue 9, 2007, Pages 938-939

  Diamond, George A ^a   Kaul, Sanjay ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

BAYES THEOREM; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; HEART INFARCTION; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK; STATISTICAL ANALYSIS;

BAYES THEOREM; CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; RISK; THIAZOLIDINEDIONES;

EID: 34548306407     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Jaynes ET. Probability theory: the logic of science. Cambridge, England: Cambridge University Press, 2003:257-60.
2. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001;134:550-60.
3. Friedrich JO, Adhikari NKJ, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007;7:5-11.